At diagnosis 24 terms
- Adenocarcinoma
- The most common cancer type in this region. Starts in the glandular cells lining the inside of an organ.
- Benign
- Not cancer. A benign growth does not invade nearby tissue or spread.
- Carcinoma kar-sin-oh-muh
- A cancer that begins in the cells lining an organ. Most upper GI and HPB cancers are carcinomas.
- Curative intent
- Treatment given with the goal of removing or destroying all of the cancer.
- Gastroscopy
- A procedure where a flexible tube with a camera examines the oesophagus, stomach and duodenum.
- Grade
- How abnormal the cancer cells look under the microscope. A measure of how quickly the cancer tends to grow.
- HPB (hepatopancreatobiliary) hep-uh-toh-pan-kree-uh-toh-bil-ee-air-ee
- The liver, pancreas, bile ducts and gallbladder, treated by surgeons as one connected region.
- ICG fluorescence
- A dye used during surgery that lights up under near-infrared light, helping surgeons see blood supply and bile ducts clearly.
- Incidental finding
- Something unexpected found during a scan or procedure done for another reason. Many early cancers are found this way.
- Localised
- Cancer that is still confined to the organ where it began.
- Locally advanced
- Cancer that has grown into nearby tissue or lymph nodes but has not spread to distant organs.
- Malignant
- Cancerous. Able to invade nearby tissue and spread to other parts of the body.
- MDT (multidisciplinary team)
- A group of specialists who meet regularly to review your case and agree on the best treatment plan together.
- Multidisciplinary team (MDT) mul-tee-dis-uh-plin-air-ee
- The group of surgeons, oncologists, radiologists, pathologists and nurses who meet to plan your care together.
- Oncologist on-kol-uh-jist
- A doctor who specialises in treating cancer, usually with drugs (medical oncologist) or radiotherapy (radiation oncologist).
- Palliative pal-ee-uh-tiv
- Care focused on controlling symptoms and keeping quality of life high. It can be given alongside active treatment, not only near the end of life.
- Primary cancer
- The original cancer, named for where it started. A pancreatic cancer found in the liver is still pancreatic cancer.
- Prognosis
- The likely course and outlook of a cancer. It is a statistical guide, never a prediction for one person.
- Recurrence
- Cancer that has come back after a period of remission.
- Remission
- A period when the cancer has responded to treatment and signs of it have reduced or disappeared.
- Secondary cancer (metastasis)
- Cancer that has spread from where it started to another part of the body. Also called metastatic disease.
- Stage
- A description of how far a cancer has grown and spread, usually stages 1 to 4. Guides treatment decisions.
- Tumour
- A mass of abnormal cells. A tumour can be benign or malignant.
- Upper GI
- The upper part of the digestive tract: the oesophagus, stomach and the first part of the small bowel (duodenum).
On your pathology report 28 terms
- Biomarker bye-oh-mar-ker
- A measurable sign in the tumour, such as a protein or gene change, that helps predict which treatments will work.
- Biopsy
- A small tissue sample taken for testing. Most cancers are confirmed this way, though some, such as liver cancer in a cirrhotic liver, can be diagnosed from scans alone.
- Copy number change (CNV) see-en-vee
- An extra or missing copy of a gene inside cancer cells. Some genomic tests report these alongside mutations, because they can also point to targeted treatments.
- Core biopsy
- A biopsy taken with a hollow needle that removes a small cylinder of tissue.
- Differentiation
- How much cancer cells resemble normal cells. Well differentiated looks closer to normal; poorly differentiated looks very abnormal.
- Endoscopic biopsy
- A biopsy taken through an endoscope during a gastroscopy, EUS or ERCP.
- Fine needle aspiration (FNA)
- A biopsy using a very thin needle to draw out cells, often guided by endoscopic ultrasound.
- Gene fusion fyoo-zhun
- When two genes join together abnormally, creating a new instruction that can drive cancer growth. Fusions such as FGFR2 and NTRK can be matched to targeted drugs.
- HER2 her-two
- A protein found on some stomach and oesophageal cancers. If present, targeted drugs such as trastuzumab may be used.
- IDH1 and FGFR2 eye-dee-aych-wun, eff-gee-eff-ar-too
- Genes that can carry changes in some bile duct cancers. Testing for them can open up targeted treatment or clinical trial options.
- Immunohistochemistry
- Special stains used on the sample to identify proteins such as HER2 or MMR. Helps guide targeted treatment.
- Liquid biopsy (ctDNA) see-tee-dee-en-ay
- A blood test that looks for fragments of tumour DNA circulating in the bloodstream. An option for genomic testing when a tissue sample is not available.
- Lymph node
- A small filter in the immune system. Cancer often spreads to nearby lymph nodes first.
- Lymphovascular invasion
- Cancer cells seen inside tiny blood vessels or lymph channels in the sample.
- Margin
- The edge of the removed tissue. A clear (R0) margin means no cancer cells at the cut edge.
- MMR / MSI em-em-ar, em-es-eye
- Mismatch repair testing. Shows whether a tumour has a particular DNA repair fault that can point toward immunotherapy.
- Next-generation sequencing (NGS) en-jee-ess
- The laboratory method used to read many genes at once from a tumour sample, to find changes that may respond to targeted treatments or clinical trials. It is the technology behind most genomic profiling panels.
- Pathologist puh-thol-uh-jist
- The doctor who examines tissue under the microscope and writes your pathology report.
- PD-L1 pee-dee-el-one
- A protein measured on some tumours that helps predict response to immunotherapy.
- Perineural invasion
- Cancer cells seen wrapping around small nerves in the sample.
- Programmed death-ligand 1 (PD-L1)
- A protein on cancer cells that helps them hide from the immune system. Testing its level can guide immunotherapy decisions.
- R0 / R1
- R0 means the margins are clear of cancer. R1 means cancer cells were seen at the cut edge.
- Microsatellite instability (MSI)
- A DNA repair defect inside the tumour. Cancers with high MSI may respond particularly well to immunotherapy.
- Somatic mutation soh-mat-ik
- A gene change that occurred in the cancer itself, not one you were born with. Somatic mutations are what tumour profiling looks for.
- Specimen
- The tissue sample sent to the lab, whether from a biopsy or from surgery.
- TNM
- The staging system: T for tumour depth, N for lymph node involvement, M for spread to distant sites.
- Tumour board
- Another name for the MDT meeting where your scans, pathology and history are reviewed together to plan care.
- Tumour mutational burden (TMB) tee-em-bee
- A count of how many gene changes a tumour carries. A high TMB can point toward immunotherapy, because heavily mutated tumours are easier for the immune system to recognise.
Around treatment 29 terms
- Ablation
- A treatment that uses heat, cold or electrical energy to destroy tumour tissue without open surgery.
- Active surveillance
- Monitoring a slow-growing condition, such as certain pancreatic cysts, with regular scans rather than immediate surgery.
- Adjuvant
- Treatment given after surgery, to reduce the risk of the cancer returning.
- Biliary drainage
- A procedure to relieve a blocked bile duct, often by placing a stent, so bile can flow again.
- Chemoradiotherapy kee-moh-ray-dee-oh-ther-uh-pee
- Chemotherapy and radiotherapy given together, often before surgery for oesophageal cancer.
- Chemotherapy
- Anti-cancer drugs that circulate through the whole body.
- Clinical trial
- A research study testing a new treatment. Can offer access to the next generation of therapies.
- Cycle
- One round of chemotherapy: treatment on certain days followed by a rest period. Treatment is counted in cycles.
- Distal pancreatectomy dis-tul pan-kree-uh-tek-tuh-mee
- Surgery to remove the body or tail of the pancreas.
- Embolisation em-boh-lie-zay-shun
- A procedure that blocks the blood supply to a liver tumour, sometimes combined with chemotherapy or radiation beads.
- Endoscopic mucosal resection (EMR)
- Removal of very early-stage tumours or pre-cancerous tissue through an endoscope, without external incisions.
- FOLFIRINOX fol-fee-ree-noks
- A combination chemotherapy regimen commonly used for pancreatic cancer.
- Gastrectomy gas-tek-tuh-mee
- Surgery to remove part (partial) or all (total) of the stomach.
- Gemcitabine jem-sit-uh-been
- A chemotherapy drug often used for pancreatic and biliary cancers.
- Hepatectomy hep-uh-tek-tuh-mee
- Surgery to remove part of the liver.
- Immunotherapy
- Treatments that help your own immune system recognise and attack cancer cells.
- Keyhole surgery
- Surgery done through several small cuts using a camera and instruments (laparoscopic or robotic), rather than one large incision.
- Multimodal therapy
- Combining two or more types of treatment, usually chemotherapy, radiation and surgery, for the best chance of cure.
- Neoadjuvant
- Treatment given before surgery, usually to shrink the tumour.
- Oesophagectomy oh-sof-uh-jek-tuh-mee
- Surgery to remove part or all of the oesophagus, often with the stomach pulled up to replace it.
- Patient-reported outcomes (PROs)
- Information about symptoms and quality of life reported directly by you, not interpreted by a clinician.
- Portal vein
- The main vein carrying blood from the gut to the liver. Whether a tumour touches it affects whether surgery is possible.
- Prehabilitation
- A program of exercise, nutrition and psychological support before major treatment, to help you cope better with it and recover faster.
- Radiotherapy
- High-energy beams targeted at the tumour.
- Resectable
- Able to be removed by surgery.
- Stent
- A small tube placed in a blocked bile duct or oesophagus to keep it open.
- Targeted therapy
- Drugs that block specific molecules a cancer needs to grow. Only work if the tumour carries the target.
- Unresectable
- Not able to be removed by surgery, usually because of where it is or how far it has spread. Other treatments still apply.
- Whipple (pancreaticoduodenectomy) whip-ul, pan-kree-uh-toh-doo-oh-dee-neh-dek-tuh-mee
- A major operation to remove the head of the pancreas and nearby structures. The standard operation for cancers in that location.
Radiology & scans 23 terms
- Angiography an-jee-og-ruh-fee
- Imaging of the blood vessels, used to check whether a tumour involves major arteries or veins.
- CA 19-9
- A blood protein that can be elevated in pancreatic and biliary cancers. Used alongside scans to monitor response, but NOT a screening test on its own.
- Contrast
- A dye given by injection or by mouth that makes organs and blood vessels show up more clearly on scans.
- CT scan
- Detailed X-ray images built into a 3D picture. The main scan for diagnosis and staging.
- CT-guided biopsy
- A biopsy where the needle is positioned using a CT scan, often used for liver or pancreatic samples.
- Diagnostic laparoscopy lap-uh-ros-kuh-pee
- A keyhole operation to look inside the abdomen directly, used to check for tiny spread that scans can miss before major surgery. Also called staging laparoscopy.
- Doppler ultrasound
- An ultrasound that shows blood flow in vessels, used to check the portal vein and liver vessels.
- Endoscopy (gastroscopy)
- A thin camera passed through the mouth to look at the oesophagus and stomach.
- ERCP
- An endoscope used to image the bile ducts and often to place a stent.
- EUS (endoscopic ultrasound)
- An ultrasound probe on an endoscope, so the scan happens from inside, right next to the pancreas.
- Fluoroscopy floor-os-kuh-pee
- Real-time X-ray imaging used during some procedures to guide instruments.
- Functional imaging
- Scans that show not just structure but also how tissues are working. PET and HIDA scans are examples.
- HIDA scan
- A nuclear medicine scan that traces bile flow from the liver through the bile ducts and into the bowel.
- Interval imaging
- Scans taken at regular set times after treatment to check for any change, rather than waiting for symptoms.
- Interventional radiologist
- A doctor who uses imaging to guide needles and tubes for biopsies, drains and stents.
- Liver ultrasound
- A quick, radiation-free scan using sound waves, often the first test for the liver and bile ducts.
- MRCP
- A special MRI that pictures the bile ducts and pancreatic duct.
- MRI
- Detailed images made with magnets and radio waves, without radiation.
- MRI liver (hepatobiliary MRI)
- A specialised MRI with a contrast agent taken up by liver cells, used to characterise liver lesions.
- PET scan
- A scan that shows where cells are most active, used to check for spread.
- Radiologist ray-dee-ol-uh-jist
- The doctor who reads your scans and writes the imaging report.
- Radiomics
- Computer analysis of scan images to detect patterns the human eye might miss, increasingly used in research and clinical trials.
- Ultrasound-guided biopsy
- A biopsy where the needle is positioned using an ultrasound scan.
Monitoring & blood tests 25 terms
- Albumin
- A protein made by the liver that keeps fluid in your blood vessels and carries substances around the body. A low level can be a sign of poor nutrition or liver strain.
- Alkaline phosphatase (ALP)
- An enzyme found in the liver, bile ducts and bone. Rising levels can point to a blockage or disease progression.
- Anaemia uh-nee-mee-uh
- A lower-than-normal level of red blood cells or haemoglobin, causing tiredness and breathlessness.
- APTT
- Activated partial thromboplastin time. Another measure of how your blood clots, often checked alongside INR before surgery or while you are on blood thinners.
- Bilirubin bil-ih-roo-bin
- A yellow pigment made when old red blood cells are broken down. A high level causes jaundice and can signal a blocked bile duct.
- CA19-9 see-ay-nine-teen
- A tumour marker blood test most often used for pancreatic and biliary cancers. It is a trend to watch over time, not a diagnosis on its own.
- CEA (carcinoembryonic antigen)
- A blood protein that can be elevated in several GI cancers. Used for monitoring, not diagnosis.
- CEA see-ee-ay
- Carcinoembryonic antigen. A tumour marker blood test used for some stomach and bowel cancers.
- Complete blood count (CBC)
- A routine blood test that counts your red cells, white cells and platelets. Important before and during chemotherapy.
- CRP (C-reactive protein)
- A blood test that measures inflammation in the body.
- eGFR and creatinine
- Creatinine is a waste product your kidneys filter out, and eGFR is a number calculated from it that estimates how well your kidneys are working. A falling eGFR means the kidneys are under strain, which can affect how some treatments are dosed.
- Electrolytes
- Minerals in your blood that keep your heart, muscles and nerves working, including sodium, potassium, calcium and magnesium. Treatment and dehydration can push them out of range.
- FBC (full blood count)
- A single blood test that measures your red blood cells, white blood cells and platelets. It is the most common monitoring test, repeated at nearly every visit to check that your blood can carry oxygen, fight infection and clot properly.
- Febrile neutropenia feb-rile new-troh-pee-nee-uh
- A low white cell count together with a fever. It is an emergency during chemotherapy and needs urgent antibiotics.
- Follow-up (surveillance)
- The schedule of scans and blood tests after treatment ends, to watch for any sign of the cancer returning.
- Haemoglobin
- The protein in red blood cells that carries oxygen around your body. A low level is called anaemia and can cause tiredness and breathlessness.
- INR
- International Normalised Ratio. A measure of how quickly your blood clots. A higher INR means slower clotting, checked before surgery and watched closely if you are taking blood-thinning medication.
- Jaundice jon-diss
- Yellowing of the skin and eyes caused by a build-up of bilirubin, often from a blocked bile duct.
- LFTs (liver function tests)
- A group of blood tests that show how well your liver and bile ducts are working. They include bilirubin and the enzymes ALT, AST and ALP. Rising levels can signal a blockage or inflammation that needs attention.
- Neutropenia new-troh-pee-nee-uh
- A low level of neutrophils, the infection-fighting white cells, raising the risk of infection.
- Neutrophils
- A type of white blood cell that is first to fight infection. Chemotherapy can lower their number, so your team checks them before each cycle. A low count is called neutropenia and may mean treatment needs a short pause.
- Performance status
- A score from 0 to 4 of how well you can carry out daily activities, used to judge whether treatment is tolerable.
- Platelets
- Small cell fragments that help your blood clot and stop bleeding. A low platelet count, common during chemotherapy, can cause easy bruising or bleeding.
- Tumour marker
- A substance in the blood, such as CA19-9 or CEA, that can rise with some cancers and is tracked over time.
- White blood cells (WBC)
- The cells that fight infection, measured on a full blood count.
Family risk 22 terms
- BRCA1 / BRCA2
- Genes that repair DNA. Inherited changes in them raise the risk of several cancers and can open up targeted treatments.
- BRCA2
- A gene that normally protects against cancer. Inherited changes in BRCA2 raise the risk of pancreatic, breast and other cancers.
- Cascade testing
- Testing relatives one generation at a time after a gene change is found in the family.
- CDH1 see-dee-aitch-one
- A gene linked to hereditary diffuse gastric cancer. Families with several stomach cancers may be tested for it.
- Familial pancreatic cancer
- A term used when two or more close relatives have had pancreatic cancer, suggesting a possible inherited tendency.
- Familial risk
- A higher-than-average risk because several relatives have had the same or related cancers, even without a single identified gene.
- Family history
- The record of cancers in your blood relatives, used to judge whether genetic testing is appropriate.
- Gene mutation (variant)
- A change in a gene. Some changes raise cancer risk; many are harmless.
- Genetic counsellor
- A specialist who explains genetic testing, supports your decision, and coordinates family testing.
- Genetic test
- A blood or saliva test that looks for inherited gene changes that raise cancer risk.
- Germline jerm-line
- A gene change present in every cell of the body and able to be passed to children. Different from changes found only in the tumour.
- Germline testing
- Testing DNA from a blood or saliva sample, not the tumour, to see if you were born with a gene change that raises cancer risk.
- Hereditary
- Passed down through a family via genes. Only a small number of these cancers are hereditary.
- Lynch syndrome
- An inherited condition that raises the risk of several cancers, including stomach and biliary cancers.
- PALB2 pal-bee-two
- A gene linked to pancreatic cancer risk.
- Peutz-Jeghers syndrome puts-ye-gers
- A rare inherited condition causing polyps and a higher risk of several GI cancers.
- Risk-reducing surgery
- An operation to remove an organ at very high risk before cancer develops, considered in some inherited syndromes.
- Screening
- Regular checks for people at higher risk, to find cancer early or before it develops.
- Somatic soh-mat-ik
- A gene change found only in the tumour, not inherited and not passed on.
- Sporadic
- Happening by chance, not inherited. Most upper GI and HPB cancers are sporadic.
- STK11
- A gene linked to Peutz-Jeghers syndrome. Inherited changes raise the risk of several GI cancers, including pancreatic.
- Tumour profiling
- Testing the cancer's own DNA for targetable changes. Different from testing the genes you were born with.
No terms match your search. Try a different word, or switch the filter above back to “All terms”.